Titre :

Early experience with new transcatheter mitral valve replacement

Auteur(s) :

Bapat, Vinayak [Auteur]
Rajagopal, Vivek [Auteur]
Meduri, Christopher [Auteur]
Farivar, R Saeid [Auteur]
Walton, Antony [Auteur]
Duffy, Stephen J. [Auteur]
Gooley, Robert [Auteur]
Almeida, Aubrey [Auteur]
Reardon, Michael J. [Auteur]
Kleiman, Neal S. [Auteur]
Spargias, Konstantinos [Auteur]
Pattakos, Stratis [Auteur]
Ng, Martin K. [Auteur]
Wilson, Michael [Auteur]
Adams, David H. [Auteur]
Leon, Martin B. [Auteur]
Mack, Michael J. [Auteur]
Chenoweth, Sharla [Auteur]
Sorajja, Paul [Auteur]

Titre de la revue :

Journal of the American College of Cardiology

Nom court de la revue :

J. Am. Coll. Cardiol.

Numéro :

71

Pagination :

12-21

Date de publication :

2018-01-02

ISSN :

0735-1097

Mot(s)-clé(s) en anglais :

transcatheter mitral valve replacement
prosthesis
mitral valve regurgitation

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

Transcatheter mitral valve replacement (TMVR) is a potential therapy for patients with symptomatic, severe mitral regurgitation (MR). The feasibility of this therapy remains to be defined. The authors report their early ...
Lire la suite >Transcatheter mitral valve replacement (TMVR) is a potential therapy for patients with symptomatic, severe mitral regurgitation (MR). The feasibility of this therapy remains to be defined. The authors report their early experience with TMVR using a new valve system. The valve is a self-expanding, nitinol valve with bovine pericardial leaflets that is placed using a transapical delivery system. Patients with symptomatic MR who were deemed high or extreme risk by the local heart teams were enrolled in a global pilot study at 14 sites (United States, Australia, and Europe). Fifty consecutively enrolled patients (mean age: 73 ± 9 years; 58.0% men; 84% secondary MR) underwent TMVR with the valve. The mean Society for Thoracic Surgery score was 6.4 ± 5.5%; 86% of patients were New York Heart Association functional class III or IV, and the mean left ventricular ejection fraction was 43 ± 12%. Device implant was successful in 48 patients with a median deployment time of 14 min (interquartile range: 12 to 17 min). The 30-day mortality was 14%, with no disabling strokes, or repeat interventions. Median follow-up was 173 days (interquartile range: 54 to 342 days). At latest follow-up, echocardiography confirmed mild or no residual MR in all patients who received implants. Improvements in symptom class (79% in New York Heart Association functional class I or II at follow-up; p < 0.0001 vs. baseline) and Minnesota Heart Failure Questionnaire scores (56.2 ± 26.8 vs. 31.7 ± 22.1; p = 0.011) were observed. TMVR with the valve was feasible in a study group at high or extreme risk for conventional mitral valve replacement. These results inform trial design of TMVR in lower-risk patients with severe mitral valve regurgitation (Evaluation of the Safety and Performance of the Twelve Intrepid Transcatheter Mitral Valve Replacement System in High Risk Patients with Severe, Symptomatic Mitral Regurgitation - The Twelve Intrepid TMVR Pilot Study; NCT02322840).Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

CHU Lille
CNRS
Inserm
Université de Lille

Collections :

• Lille Neurosciences & Cognition (LilNCog) - U 1172

Équipe(s) de recherche :

Troubles cognitifs dégénératifs et vasculaires

Date de dépôt :

2019-11-27T14:29:40Z